Maximal Multistage Shuttle Run Test-induced Myalgia in a Patient with Muscle Phosphorylase B Kinase Deficiency

Asami Munekane¹, Yutaka Ohsawa¹, Tokiko Fukuda², Hirotake Nishimura³, Shin-ichiro Nishimatsu¹, Hideo Sugie³, Yoshihiko Saito⁶, Ichizo Nishino⁵ and Yoshihide Sunada¹

Abstract:
Muscle phosphorylase b kinase (PHK) deficiency is a rare mild metabolic disorder caused by mutations of the PHKA1 gene encoding the αM subunit of PHK. A 16-year-old boy experienced myalgia during the maximal multistage 20-m shuttle run test targeting the maximal oxygen consumption. Although an ischemic forearm exercise test was normal, a muscle biopsy revealed subsarcolemmal glycogen accumulation. He harbored a novel insertion mutation in the PHKA1 gene that resulted in premature termination of the αM subunit close to the C-terminus. Compared with previously reported cases, his reduction in PHK activity was relatively mild.

Key words: muscle phosphorylase b kinase (PHK), αM subunit of the PHK gene (PHKA1), glycogen storage disease type IXd, maximal multistage 20-m shuttle run test

(Intern Med Advance Publication) (DOI: 10.2169/internalmedicine.8137-21)

Introduction

Phosphorylase b kinase (PHK) is a key enzyme involved in glycogen breakdown by phosphorylating glycogen phosphorylase, thereby inducing a change from its inactive (b) to active (a) form (1). PHK comprises four subunits with stoichiometry of α4β4γ4δ4. The γ subunit is catalytic, the α and β subunits are regulatory, and the δ subunit is identical to calmodulin. The α subunit has two different isoforms that show tissue-specific expression in the muscle (αM) or liver (αL) and are encoded by distinct genes on the X chromosome (PHKA1 and PHKA2, respectively).

In previous studies involving enzyme activity measurements, muscle PHK deficiency presented with three clinical phenotypes (2): (i) juvenile and adult-onset exercise intolerance; (ii) late-onset slowly-progressive muscle weakness; and (iii) neonatal-onset floppy infant syndrome. To date, only eight cases of muscle PHK deficiency (glycogen storage disease type IXd) have been reported with the identification of mutations in the PHKA1 gene encoding the muscle-specific αM subunit (1, 3-10).

We herein report a patient with muscle PHK deficiency caused by a novel mutation in the PHKA1 gene and provide characteristic clinical pictures.

Case Report

A 16-year-old high-school boy was admitted to our hospital suffering from exercise intolerance in the form of myalgia. His birth and development were normal. He had enjoyed playing football, swimming, and gymnastics without exercise-induced myalgia until he was 15 years old, when his first episode of myalgia occurred during the maximal multistage 20-m shuttle run test (11) to target the maximal oxygen consumption in a handball club activity. Subsequently, he repeatedly suffered from muscle pain that gradually spread from the calf to the thigh during the incremental
exercise intensity associated with the shuttle run test. Occasionally, he had episodes of hyperventilation due to myalgia and noted pigmenturia after the muscle pain disappeared the next morning.

His parents were non-consanguineous. No other family members had similar symptoms. We decided to make a differential diagnosis of various diseases presenting with exercise intolerance and/or myalgia such as glycogen storage diseases, disorders of fatty acid metabolism, and mitochondrial myopathies.

Findings on a physical examination at admission were normal, with no muscle atrophy or weakness and no organomegaly. His serum creatine kinase (CK) levels were ranging from 213 to 2,027 U/L (normal range: 54-248 U/L). An ischemic forearm exercise test showed normal elevation (>5-fold) of plasma lactate (Table 1). However, a muscle biopsy from the left vastus lateralis muscle revealed subsarcolemmal glycogen accumulation in some myofibers (Fig. 1). Biochemical analyses demonstrated a decrease in PHK activity (4.5 nmol/min/mg; normal range: 18.6-68.6 nmol/min/mg; Table 2) in the muscle biopsy homogenate, but not in red blood cells (data not shown). Interestingly, the in vitro anaerobic lactate production rate was significantly decreased with glycogen as a substrate, but not glucose-1-P as a substrate, when the muscle biopsy homogenate was used as an enzyme source (Fig. 2).

Using a next-generation sequencer (IonPGMTM; Thermo Fisher Scientific, Waltham, MA, United States), targeted re-sequencing of 41 metabolic myopathy-related genes (12) identified a previously unreported mutation in the PHKA1 gene, comprising a single nucleotide insertion that created a premature stop codon (c.3579_3580insT, p.S1194*) in exon 32 (Fig. 3). This mutation has not been reported in the public databases of the general population such as gnomAD, 1,000 genomes, ToMMo, and HGMD.

**Discussion**

Muscle PHK deficiency is a very rare disease among glycogen storage diseases. Table 3 summarizes the characteristics of nine cases of glycogen storage disease type IXd harbouring mutations in the PHKA1 gene, including our case. Of these, six cases showed exercise intolerance in the form of myalgia, cramps, or early fatigue; four exhibited progres-

| Table 1. Ischemic Forearm Exercise Test. |
|-----------------------------------------|
|                    Pre-exercise | Post-exercise |
|                        |   | 0 min | 2 min | 4 min | 6 min |
| Lactate (mg/dL) | 14.1 | 50.7 | 37.1 | 29.9 | 25.5 |
| Pyruvate (mg/dL) | 0.53 | 1.00 | 0.77 | 0.76 | 0.73 |
| Ketone (μmol/L) | 54.5 | 31.2 | 41.4 | 45.1 | 45.7 |
| Ammonia (μg/dL) | 51 | 161 | 136 | 108 | 101 |

Figure 1. Fresh-frozen cryosections from the left vastus lateralis muscle. The subsarcolemmal vacuoles in some myofibers are filled with glycogen. (A) Hematoxylin and Eosin staining. (B) Periodic acid-Schiff staining of an epon-embedded section. Insets are enlarged images of the boxed regions.
Figure 2. In vitro anaerobic lactate production rates. Bars indicate the average values of duplicate measurements. The lactate production rate in the muscle biopsy homogenate was measured using glycerogen or glucose-1-P as the substrate. Note that the breakdown activity of glycogen into glucose-1-P was impaired in muscle.

Table 2. Activities of Glycolytic/glycogenolytic Enzymes in Skeletal Muscle.

| ENZYMES                             | PATIENT | CONTROL RANGE |
|-------------------------------------|---------|---------------|
| Phosphorylase (+AMP)                | 83.3    | 33.3–89.3     |
| Phosphorylase b kinase              | 4.5     | 18.5–68.6     |
| Phosphoglucomutase                  | 267.7   | 221.1–562.0   |
| Phosphohexoisomerase                | 1,231.9 | 669.1–1,204.0 |
| Phosphofructokinase                 | 135.2   | 33.7–88.5     |
| Aldolase                            | 323.1   | 246.7–580.0   |
| Glyceraldehyde-3-P-dehydrogenase    | 1,643.8 | 1,577.8–3,107.2 |
| Phosphoglycerate kinase             | 1,378.7 | 658.3–1,470.2 |
| Phosphoglycerate mutase             | 830.2   | 687.7–1,491.5 |
| Enolase                             | 430.4   | 224.6–692.5   |
| Pyruvate kinase                     | 1,531.3 | 837.8–2,075.3 |
| Lactate dehydrogenase               | 1,198.8 | 1,029.3–2,734.4 |

All enzymatic activities are expressed as nmol substrate utilized/min/mg protein.

sive muscle weakness; and two had asymptomatic hyperCKemia. Since myophosphorylase activation is impaired under conditions of PHK deficiency, it is expected that symptoms similar to McArdle disease, which is caused by a primary myophosphorylase defect, may occur, such as exercise intolerance. However, in reality, patients with PHK deficiency present with extremely mild symptoms, sometimes being almost asymptomatic despite mild impairment of muscle glycogenolysis, elevated CK levels, and glycogen accumulation in the muscle. In the present case report, the patient had been asymptomatic during regular exercise until myalgia was first induced by the maximal multistage 20-m shuttle run test, a very-high-intensity exercise designed to target the maximal oxygen consumption. If he had not undergone the 20-m shuttle run test, he might not have been diagnosed with PHK deficiency.

Another pitfall in the diagnosis of PHK deficiency is that, unlike McArdle disease, lactate increases normally in a forearm ischemic exercise test, which is commonly performed as a screening test for glycosgenosis. Interestingly, in vitro experiments revealed decreased lactate production when glycogen was supplied to the muscle biopsy homogenate from the patient despite a normal elevation of lactate in the forearm ischemic exercise test. This can be explained by the integration of various stimuli in the regulation of myophosphorylase activity in vivo. At the beginning of exercise, calcium stores are released from the sarcoplasmic reticulum, causing activation of phosphorylase kinase and subsequent phosphorylation and activation of myophosphorylase (13). Glycogen phosphorylase is allosterically activated by increased [Pi] within the cell and is activated by high AMP levels (1). The ischemic forearm exercise test is not diagnostically helpful in patients with PHK deficiency, as these variable factors co-regulate glycolysis.

Our patient harbored a novel mutation in the PHKA1 gene that resulted in premature termination of the αM
subunit of PHK close to its C-terminus (Fig. 3A). This mutation is considered to cause a defect in the S-farnesyl cysteine site (Fig. 3B), which plays a role in directing the αM subunit to the membrane (14, 15). Although the decrease in enzyme activity was relatively mild in the present case, no correlations between the mutation site, residual muscle PHK activity, or severity of clinical symptoms were found in comparison with previously reported cases (Table 3). Unfor-
fortunately, genetic testing of family members was not allowed, so we were unable to conclude whether the patient’s genetic mutation occurred in de novo or was due to X-linked inheritance.

In conclusion, a submaximal to maximal incremental aerobic exercise test can facilitate the diagnosis of muscle PHK deficiency (glycogen storage disease type IXd), which may be underdiagnosed because of the very mild symptoms and normal reaction in the ischemic forearm exercise test. It is important to include this disease in the differential diagnosis of exercise intolerance.

The authors state that they have no Conflict of Interest (COI).

Funding
This study was funded by a Research on Rare and Intractable Diseases, Health and Labour Sciences Research Grant from the Ministry of Health, Labour and Welfare of Japan (H29-NanCre-nitu(Nan)-Ippan-068) and Intramural Research Grants (29-4, 2-5) for Neurological and Psychiatric Disorders from the National Institute of Neuroscience

Acknowledgments
We are grateful to M. Tsuboi (Department of Neurology, Kawasaki Medical School) for technical assistance. We also thank Alison Sherwin, PhD, from Edanz Group (https://en-author-services.edanz.com/ac) for editing a draft of this manuscript.

References
1. Orngreen MC, Schelhaas HJ, Jeppesen TD, et al. Is muscle glycogenolysis impaired in X-linked phosphorylase b kinase deficiency? Neurology 70: 1876-1882, 2008.
2. Burwinkel B, Hu B, Schroers A, et al. Muscle glycogenosis with low phosphorylase kinase activity: mutations in PHKA1, PHKG1 or six other candidate genes explain only a minority of cases. Eur J Hum Genet 11: 516-526, 2003.
3. Abarbanel JM, Bashan N, Potashnik R, Osimani A, Moses SW, Herishanu Y. Adult muscle phosphorylase “b” kinase deficiency. Neurology 36: 560-562, 1986.
4. Clemens PR, Yamamoto M, Engel AG. Adult phosphorylase b kinase deficiency. Ann Neurol 28: 529-538, 1990.
5. Wilkinson DA, Tonin P, Shanske S, Lombes A, Carlson GM, DiMauro S. Clinical and biochemical features of 10 adult patients with muscle phosphorylase kinase deficiency. Neurology 44: 461-466, 1994.
6. Wehner M, Clemens PR, Engel AG, Kilimann MW. Human muscle glycogenosis due to phosphorylase kinase deficiency associated with a nonsense mutation in the muscle isozyme of the alpha subunit. Hum Mol Genet 3: 1983-1987, 1994.
7. Bruno C, Manfredi G, Andreu AL, et al. A splice junction mutation in the cM gene of the phosphorylase kinase in a patient with myopathy. Biochem Biophys Res Commun 249: 648-665, 1998.
8. Wuyts W, Reyniers E, Ceuterick C, Storm K, de Barys T, Martin JJ. Myopathy and phosphorylase kinase deficiency caused by a mutation in the PHKA1 gene. Am J Med Genet A 133A: 82-84, 2005.
9. Echaniz-Laguna A, Akman HO, Mohr M, et al. Muscle phosphorylase b kinase deficiency revisited. Neuromuscul Disord 20: 125-127, 2010.
10. Peisler N, Orngreen MC, Echaniz-Laguna A, et al. Muscle phosphorylase kinase deficiency: a neutral metabolic variant or a disease? Neurology 78: 265-268, 2012.
11. Léger LA, Lambert J. A maximal multistage 20-m shuttle run test to predict VO2 max. Eur J Appl Physiol Occup Physiol 49: 1-12, 1982.
12. Nishikawa A, Mitsuhashi S, Miyata N, Nishino I. Targeted massively parallel sequencing and histological assessment of skeletal muscles for the molecular diagnosis of inherited muscle disorders. J Med Genet 54: 104-110, 2017.
13. Greenberg CC, Jurczak MJ, Danos AM, Brady MJ. Glycogen branches out: new perspectives on the role of glycogen metabolism in the integration of metabolic pathways. Am J Physiol Endocrinol Metab 291: E1-E8, 2006.
14. Heilmeyer LM, Serwe M, Weber C, Hoffmann-Posorske E, Meyer HE. Farnesylcysteine, a constituent of the alpha and beta subunits of rabbit skeletal muscle phosphorylase kinase: localization by conversion to S-ethylcysteine and by tandem mass spectrometry. Proc Natl Acad Sci U S A 89: 9554-9558, 1992.
15. Ayers NA, Wilkinson DA, Fitzgerald TJ, Carlson GM. Self-association of the alpha subunit of phosphorylase kinase as determined by two-hybrid screening. J Biol Chem 274: 35583-35590, 1999.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).